MBCProject_7544_T1_RNA
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.630
- INTERFERON_GAMMA_RESPONSE+0.580
- ALLOGRAFT_REJECTION+0.530
- IL6_JAK_STAT3_SIGNALING+0.460
- INFLAMMATORY_RESPONSE+0.390
- IL2_STAT5_SIGNALING+0.320
- COMPLEMENT+0.300
- APICAL_JUNCTION+0.250
- KRAS_SIGNALING_DN+0.250
- KRAS_SIGNALING_UP+0.250
Top 10 suppressed
- PROTEIN_SECRETION-0.420
- OXIDATIVE_PHOSPHORYLATION-0.380
- ANDROGEN_RESPONSE-0.340
- ESTROGEN_RESPONSE_EARLY-0.310
- ADIPOGENESIS-0.300
- PEROXISOME-0.300
- TGF_BETA_SIGNALING-0.260
- DNA_REPAIR-0.240
- FATTY_ACID_METABOLISM-0.240
- GLYCOLYSIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OL-A66I-01A-21R-A29R-07 | — | D | 0.891 |
| 2 | TCGA-AC-A8OQ-01A-11R-A41B-07 | — | D | 0.877 |
| 3 | TCGA-A2-A0ST-01A-12R-A084-07 | — | D | 0.870 |
| 4 | TCGA-EW-A3U0-01A-11R-A22K-07 | — | D | 0.870 |
| 5 | AUR-AFR5-TTP1-A-1-1-R-A743-41 | — | D | 0.865 |
| 6 | TCGA-A2-A04Q-01A-21R-A034-07 | — | D | 0.847 |
| 7 | TCGA-E9-A3QA-01A-61R-A22K-07 | — | D | 0.839 |
| 8 | TCGA-BT-A42E-01A-11R-A23W-07 | — | — | 0.832 |
| 9 | TCGA-PL-A8LZ-01A-31R-A36F-07 | — | D | 0.832 |
| 10 | TCGA-C8-A12V-01A-11R-A115-07 | — | D | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.210 | Inavolisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.130 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |